After Mizuho Securities and Canaccord Genuity assigned a Buy rating to Aerie Pharma in the last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Elemer Piros reiterated a Buy rating on Aerie Pharma (NASDAQ: AERI) today and set a price target of $86. The company’s shares opened today at $49.95.
Piros observed:
“Aerie reported 1Q18 financial results and provided encouraging initial revenue guidance for the first year of the Rhopressa launch ($20-30 million).”
According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -4.1% and a 47.6% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Currently, the analyst consensus on Aerie Pharma is Strong Buy and the average price target is $81.75, representing a 63.7% upside.
In a report issued on April 30, Mizuho Securities also maintained a Buy rating on the stock with a $77 price target.
See today’s analyst top recommended stocks >>
Based on Aerie Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $58.51 million. In comparison, last year the company had a GAAP net loss of $25.79 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company’s product candidates are Rhopressa and Roclatan. Aerie Pharmaceuticals was founded by David L. Epstein, Casey C.
